Alphatec Holdings (ATEC) Could Be 45% Below Fair Value Following Its Recent Rebound

Alphatec Holdings (ATEC) has drawn fresh attention after recent trading moves, with the stock priced at US$9.58 and showing mixed short term returns that contrast with weaker performance over the past 3 years.

See our latest analysis for Alphatec Holdings.

Against a backdrop of weaker long term total shareholder returns, Alphatec Holdings has recently seen momentum pick up, with a 1 month share price return of 15.70% and a year to date share price decline of 53.85%. This contrasts with a 1 year total shareholder return fall of 12.19% and a 3 year total shareholder return fall of 48.82%.

If you are weighing Alphatec Holdings against other opportunities in medical technology and beyond, this could be a useful moment to broaden your watchlist and check out 40 healthcare AI stocks

Given Alphatec Holdings’ sharp recent rebound but still weak multi year returns, the real tension is between stepping in after this bounce and holding off for a potentially cheaper entry. So how does the current valuation stack up?

Most Popular Narrative: 45% Undervalued

At a last close of $9.58 versus a narrative fair value of about $17.33, Alphatec Holdings is framed as materially discounted, with that gap built on detailed forecasts for revenue, margins, and future valuation multiples.

Ongoing innovation in integrated procedural solutions and the forthcoming launch of Valence (robotics/navigation) positions the company to capitalize on the accelerating adoption of advanced healthcare technologies, likely boosting both future revenue and long-term margin expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that fair value gap? The narrative leans on fast improving earnings, richer margins, and a future profit multiple that assumes meaningful execution. Curious which specific revenue path and profitability step change are doing the heavy lifting here?

Result: Fair Value of $17.33 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the Alphatec Holdings narrative still faces pressure from ongoing operating losses and heavy R&D needs, along with intense competition from larger medical device companies.

Find out about the key risks to this Alphatec Holdings narrative.

Next Steps

Mixed signals around Alphatec Holdings can be hard to parse, so consider reviewing the full data set and weighing both sides before forming a view. To see the balance of concerns and potential upsides in one place, check out the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Alphatec Holdings?

If Alphatec Holdings has your attention, do not stop there. Broaden your options now and give yourself more ways to react when markets move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com